Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir for the Treatment of Chronic Hepatitis C: A Prospective Cohort Study in Portugal
Acta Médica Portuguesa · 2024
DOI: 10.20344/amp.19178 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Acta Médica Portuguesa, 2024. Verfasst von José Vera und 14 weiteren Autor:innen. Beteiligte Einrichtung: Centro Hospitalar Barreiro-Montijo. Barreiro. Portugal. Hauptthemen laut MEDLINE: Benzimidazoles, Hepatitis C, Chronic, Quinoxalines, Antiviral Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Information about pan-genotypic treatments for hepatitis in Portugal is scarce. We aimed to evaluate the effectiveness and safety of glecaprevir plus pibrentasvir (GLE/PIB) treatment for hepatitis C virus (HCV) infection in real-world clinical practice.
Methods
An observational prospective study was implemented in six hospitals with 121 adult HCV patients who initiated treatment with GLE/PIB between October 2018 and April 2019, according to clinical practice. Eligible patients had confirmed HCV infection genotype (GT) 1 to 6 and were either treatment-naïve or had experience with interferon-, ribavirin- or sofosbuvir-based regimens, with or without compensated cirrhosis. Baseline sociodemographic and safety data are described for the total population (N = 115). Effectiveness [sustained virologic response 12 weeks after treatment (SVR12)] and patient-reported outcomes are presented for the core population with sufficient follow-up data (n = 97).
Results
Most patients were male (83.5%), aged < 65 years (94.8%), with current or former alcohol consumption (77.3%), illicit drug use (72.6%), and HCV acquisition through intravenous drug use (62.0%). HIV co-infection occurred in 22.6% of patients. The prevalence of each GT was: GT1 51.3%, GT2 1.7%, GT3 30.4%, GT4 16.5%, and GT5.6 0%. Most patients were non-cirrhotic (80.9%) and treatment-naïve (93.8%). The SVR12 rates were 97.9% (95% CI: 92.8 - 99.4), and > 95% across cirrhosis status, GT, illicit drug use, alcohol consumption, and HCV treatment experience. The adverse event rate was 2.6%, and no patient discontinued treatment due to adverse events related to GLE/PIB.
Conclusion
Consistent with other real-world studies and clinical trials, treatment with GLE/PIB showed high effectiveness and tolerability overall and in difficult-to-treat subgroups (ClinicalTrials.gov: NCT03303599).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centro Hospitalar Barreiro-Montijo. Barreiro. Portugal.
- Hospital Garcia de Orta. Almada. Portugal.
- Centro Hospitalar Lisboa Central. Lisboa. Portugal.
- Centro Hospitalar Universitário Porto. Porto. Portugal.
- Centro Hospitalar Vila Nova de Gaia/Espinho. Vila Nova de Gaia. Portugal.
- Centro Hospitalar Lisboa Norte. Lisboa. Portugal.
Zitieren
APA
Vera, J., Gomes, A., Póvoas, D., Seixas, D., Maltez, F., Pedroto, I., Maia, L., Mota, M., Vieira, M. J., Manata, M. J., Ferreira, P., Lino, S., Pereira Guedes, T., Barradas, V., & Marques, N. (2024). Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir for the Treatment of Chronic Hepatitis C: A Prospective Cohort Study in Portugal. Acta Médica Portuguesa. https://doi.org/10.20344/amp.19178
Vancouver
Vera J, Gomes A, Póvoas D, Seixas D, Maltez F, Pedroto I, et al. Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir for the Treatment of Chronic Hepatitis C: A Prospective Cohort Study in Portugal. Acta Médica Portuguesa. 2024. doi:10.20344/amp.19178
BibTeX
@article{Vera2024,
author = {Vera, José and Gomes, André and Póvoas, Diana and Seixas, Diana and Maltez, Fernando and Pedroto, Isabel and Maia, Luís and Mota, Margarida and Vieira, Maria João and Manata, Maria José and Ferreira, Paula and Lino, Sara and Pereira Guedes, Tiago and Barradas, Vânia and Marques, Nuno},
title = {Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir for the Treatment of Chronic Hepatitis C: A Prospective Cohort Study in Portugal},
journal = {Acta Médica Portuguesa},
year = {2024},
doi = {10.20344/amp.19178}
}
EUVIMED